Cervical cancer screening device company TruScreen’s chair confirmed a dual-listing on the ASX is on a near-term horizon.
Company chair Anthony Ho, who was seeking re-election, said the board had “endorsed” the idea and “taken steps” toward the process, including a presentation to
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
